

RECEIVED
CENTRAL FAX CENTER
OCT 24 2007

Appl. No. 10/576,719

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 to 3. (canceled).

Claim 4. (previously presented) A method for treating a keratoconjunctival disorder which comprises administering a therapeutically effective amount of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof to a patient in need thereof.

Claim 5. (previously presented) The method according to claim 4 wherein said keratoconjunctival disorder is dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis or filamentary keratitis.

Appl. No. 10/576,719

Claim 6. (previously presented) The method according to claim 4 wherein the administration is instillation of an eye drop.

Claims 7 to 9. (canceled)

Claim 10. (previously presented) The method according to claim 5 wherein the administration is instillation of an eye drop.

Claim 11. (previously presented) The method according to claim 4 wherein the administration is the application of an ophthalmic ointment.

Claim 12. (previously presented) The method according to claim 5 wherein the administration is the application of an ophthalmic ointment.

Claims 13 to 16. (canceled)